Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.

Curr Opin Pharmacol 2011 Dec 27;11(6):630-3. Epub 2011 Oct 27.

Department of Gastroenterology, University Hospital Leuven, Catholic University of Leuven, Belgium.

The development of the novel γ-aminobutyric acid type-B receptor (GABAB) agonist lesogaberan is presented as an example of a partly successful translational strategy in the field of gastroenterology. Data on transient lower esophageal sphincter relaxations (TLESRs) and gastroesophageal reflux inhibition from preclinical models translated well to clinical studies in healthy volunteers and patients with gastroesophageal reflux disease (GERD). Animal models have also been used successfully to predict the effect of other target mechanisms on TLESRs in humans. However, while translation of physiology to symptomatology in patients with GERD was achieved, the effect size was too small to be of clinical significance. A deeper understanding of the cause of symptoms in different patient categories is therefore required.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2011.10.011DOI Listing
December 2011
5 Reads

Publication Analysis

Top Keywords

gastroesophageal reflux
8
gastroenterology data
4
patients gastroesophageal
4
patients gerd
4
data transient
4
physiology symptomatology
4
transient lower
4
symptomatology patients
4
field gastroenterology
4
gerd achieved
4
studies healthy
4
partly successful
4
reflux disease
4
achieved size
4
translational strategy
4
strategy field
4
target mechanisms
4
lower esophageal
4
esophageal sphincter
4
translated well
4

Similar Publications